Top

Published in:

01-12-2011 | Research Paper

Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways

Authors: Olorunseun O. Ogunwobi, Chen Liu

Published in: Clinical & Experimental Metastasis | Issue 8/2011

Abstract

Advanced hepatocellular carcinoma (HCC) is an important cause of cancer mortality. Epithelial-mesenchymal transition (EMT) has been shown to be an important biological process in cancer progression and metastasis. We have focused on elucidating factors that induce EMT to promote carcinogenesis and subsequent metastasis in HCC using the BNL CL.2 (BNL) and BNL 1ME A. 7R.1 (1MEA) cell lines. BNL cells are normal hepatocytes whereas the 1MEA cells are HCC cells derived from chemical transformation of the BNL cells. Their morphological characteristics were examined. Expression levels of hepatocyte growth factor (HGF), markers of EMT and mediators of HGF signaling were determined and functional characteristics were compared. BNL cells were treated with HGF and effects on EMT-marker and mediators of HGF signaling were analyzed. BNL cells display characteristic epithelial morphology whereas 1MEA cells display mesenchymal characteristics. 1MEA cells express and secrete more HGF than BNL cells. There was significantly decreased expression of E-cadherin, albumin, AAT and increased expression of fibronectin, collagen-1, vimentin, snail and slug in 1MEA cells. There was also increased expression of cyclooxygenase-2 (COX-2), Akt and phosphorylated Akt (pAkt) in 1MEA cells. Moreover, 1MEA cells had increased migratory capacity inhibited by inhibition of COX-2 and Akt but not extracellular signal regulated kinase (ERK). Molecular mesenchymal characteristics of 1MEA cells were reversed by inhibition of COX-2, Akt and ERK. Treatment of BNL cells with HGF led to decreased expression of E-cadherin and increased expression of fibronectin, vimentin, snail, slug, COX-2, Akt, pAkt and increased migration, invasiveness and clonogenicity. We conclude that development of HCC is associated with upregulation of HGF which promotes EMT and carcinogenesis via upregulation of COX-2 and Akt. Consequently, HGF signaling may be targeted for therapy in advanced and metastatic HCC.

Available only for authorised users

Bosch FX, Ribes J, Diaz M et al (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5):S5–S16PubMedCrossRef

Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9(4):265–273PubMedCrossRef

Yang J, Mani SA, Donaher JL et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7):927–939PubMedCrossRef

Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420–1428PubMedCrossRef

Voulgari A, Pintzas A (2009) Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796(2):75–90PubMed

Kaartinen V, Voncken JW, Shuler C et al (1995) Abnormal lung development and cleft palate in mice lacking TGF-beta-3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 11(4):415–421PubMedCrossRef

Khoury H, Dankort DL, Sadekova S et al (2001) Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor. Oncogene 20(7):788–799PubMedCrossRef

Valles AM, Boyer B, Badet J et al (1990) Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line. Proc Natl Acad Sci USA 87(3):1124–1128PubMedCrossRef

Naldini L, Weidner KM, Vigna E et al (1991) Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 10(10):2867–2878PubMed

10.

Weidner KM, Hartmann G, Naldini L et al (1993) Molecular characteristics of HGF-SF and its role in cell motility and invasion. EXS 65:311–328PubMed

11.

Breuhahn K, Longerich T, Schirmacher P (2006) Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25:3787–3800PubMedCrossRef

12.

Zeisberg M, Yang CQ, Martino M et al (2007) Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282(32):23337–23347PubMedCrossRef

13.

Dooley S, Hamzavi J, Ciuclan L et al (2008) Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology 135(2):642–659PubMedCrossRef

14.

Kaimori A, Potter J, Kaimori JY et al (2007) Transforming growth factor-beta 1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 282(30):22089–22101PubMedCrossRef

15.

Lazarevich N, Cheremnova OA, Varga EV et al (2004) Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 39(4):1038–1047PubMedCrossRef

16.

Gotzmann J, Fischer ANM, Zojer M et al (2006) A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene 25(22):3170–3185PubMedCrossRef

17.

van Zijl F, Zulehner G, Petz M et al (2009) Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol 5(8):1169–1179PubMedCrossRef

18.

Fischer ANM, Herrera B, Mikula M et al (2005) Integration of Ras subeffector signaling in TGF-beta mediated late stage hepatocarcinogenesis. Carcinogenesis 26(5):931–942PubMedCrossRef

19.

Balaban YH, Us D, Hascelik G et al (2006) Hepatocellular carcinoma and cholangiocarcinoma are associated with high serum levels of hepatocyte growth factor. Indian J Gastroenterol 25(4):223–224PubMed

20.

Xie Q, Liu KD, Hu MY et al (2001) SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma. World J Gastroenterol 7(6):816–820PubMed

21.

Son G, Hirano T, Seki E et al (2006) Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. J Hepatol 45(5):688–695PubMedCrossRef

22.

Ding W, You HN, Dang H et al (2010) Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology 52(3):945–953PubMedCrossRef

23.

Whittaker S, Marais R, Zhu AX (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29(36):4989–5005PubMedCrossRef

24.

Matsumoto K, Nakamura T (1996) Emerging multipotent aspects of hepatocyte growth factor. J Biochem 119(4):591–600PubMed

25.

Li XY, Zhan XR, Lu C et al (2010) Mechanisms of hepatocyte growth factor-mediated signaling in differentiation of pancreatic ductal epithelial cells into insulin-producing cells. Biochem Biophys Res Commun 398(3):389–394PubMedCrossRef

26.

Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103(2):211–225PubMedCrossRef

27.

Moore AE, Greenhough A, Roberts HR et al (2009) HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis 30(10):1796–1804PubMedCrossRef

28.

Abiru S, Nakao K, Ichikawa T et al (2002) Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 35(5):1117–1124PubMedCrossRef

29.

Gonzales AJ, Goldsworthy TL, Fox TR (1998) Chemical transformation of mouse liver cells results in altered cyclin D CDK protein complexes. Carcinogenesis 19(6):1093–1102PubMedCrossRef

30.

Ogunwobi OA, Beales ILP (2006) Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways. Regul Pept 134(1):1–8PubMedCrossRef

31.

Ogunwobi O, Mutungi G, Beales ILP (2006) Leptin stimulates proliferation and inhibits apoptosis in Barrett’s esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 147(9):4505–4516PubMedCrossRef

32.

Zhu HZ, Dong HJ, Eksioglu E et al (2007) Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 133:1649–1659PubMedCrossRef

33.

Behrens J, Mareel MM, Vanroy FM et al (1989) Dissecting tumor cell invasion—epithelial cellsacquireinvasivepropertiesafterthelossofuvomorulin-mediatedcell-cell adhesion. J Cell Biol 108(6):2435–2447PubMedCrossRef

34.

Thompson EW, Torri J, Sabol M et al (1994) Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis 12(3):181–194PubMedCrossRef

35.

Guan F, Handa K, Hakomori SI (2009) Specific glycosphingolipids mediate epithelial-to-mesenchymal transition of human and mouse epithelial cell lines. Proc Natl Acad Sci USA 106(18):7461–7466PubMedCrossRef

36.

Campard D, Lysy PA, Najimi M et al (2008) Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology 134(3):833–848PubMedCrossRef

37.

Har CH, Keong CK (2005) Effects of tocotrienols on cell viability and apoptosis in normal murine liver cells (BNL CL.2) and liver cancer cells (BNL 1ME A.7R.1), in vitro. Asia Pac J Clin Nutr 14(4):374–380PubMed

38.

Shangguan DH, Meng L, Cao ZHC et al (2008) Identification of liver cancer-specific aptamers using whole live cells. Anal Chem 80(3):721–728PubMedCrossRef

39.

Hsieh HL, Wu CB, Sun CC et al (2006) Sphingosine-1-phosphate induces COX-2 expression via PI3K/Akt and p42/p44 MAPK pathways in rat vascular smooth muscle cells. J Cell Physiol 207(3):757–766PubMedCrossRef

Title: Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways
Authors: Olorunseun O. Ogunwobi
Chen Liu
Publication date: 01-12-2011
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 8/2011
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-011-9404-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2011

Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver

Ob/ob serum promotes a mesenchymal cell phenotype in B16BL6 melanoma cells

High-dose ionizing radiation-induced hematotoxicity and metastasis in mice model

Reduction of metastasis using a non-volatile buffer

Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of β-catenin in gastric cancer

Glycolysis inhibition by 2-deoxy-d-glucose reverts the metastatic phenotype in vitro and in vivo

Keynote webinar | Spotlight on antibody–drug conjugates in cancer